|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR102576903B1
(ko)
|
2012-09-07 |
2023-09-13 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
|
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
US9963513B2
(en)
*
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
WO2014131712A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
KR102927870B1
(ko)
|
2014-02-28 |
2026-02-19 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
|
|
RS65573B1
(sr)
|
2014-08-04 |
2024-06-28 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
|
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
EP3221356B1
(en)
|
2014-11-20 |
2020-09-02 |
F.Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules against folr1 and cd3
|
|
FI4141032T3
(fi)
|
2014-11-20 |
2024-07-31 |
Hoffmann La Roche |
T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向ｂ細胞成熟抗原之嵌合型抗原受體類
|
|
IL310723A
(en)
|
2015-04-13 |
2024-04-01 |
Pfizer |
Therapeutic antibodies and their uses
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
AU2016302881B2
(en)
*
|
2015-08-03 |
2022-09-15 |
Bristol-Myers Squibb Company |
Monoclonal antibodies against BCMA
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017031104A1
(en)
|
2015-08-17 |
2017-02-23 |
Janssen Pharmaceutica Nv |
Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
SG11201805770UA
(en)
*
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
KR102608405B1
(ko)
|
2016-04-01 |
2023-12-01 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
US10689450B2
(en)
*
|
2016-04-01 |
2020-06-23 |
Kite Pharma, Inc |
BCMA binding molecules and methods of use thereof
|
|
US10603380B2
(en)
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
CN109641049B
(zh)
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR102512934B1
(ko)
|
2016-08-10 |
2023-03-23 |
레전드 바이오테크 아일랜드 리미티드 |
Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
|
|
US11771743B2
(en)
|
2016-09-01 |
2023-10-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an IL-4R antagonist
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
MY200988A
(en)
*
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
US10882918B2
(en)
|
2016-09-30 |
2021-01-05 |
Hoffmann-La Roche Inc. |
Bispecific T cell activating antigen binding molecules
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
EP3535295A1
(en)
|
2016-11-02 |
2019-09-11 |
EngMab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
ES3039621T3
(en)
*
|
2016-12-22 |
2025-10-23 |
Daiichi Sankyo Co Ltd |
Anti-cd3 antibody, and molecule containing said antibody
|
|
JP7280828B2
(ja)
*
|
2017-01-23 |
2023-05-24 |
クレージュ メディカル カンパニー，リミテッド |
Ｂｃｍａを標的とする抗体およびその使用
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
CA3049689A1
(en)
*
|
2017-02-06 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
|
DK3579848T3
(da)
|
2017-02-08 |
2025-01-20 |
Dragonfly Therapeutics Inc |
Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
|
|
AU2018219348A1
(en)
*
|
2017-02-10 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding BCMA, NKG2D and CD16
|
|
JP2020507605A
(ja)
|
2017-02-17 |
2020-03-12 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
|
|
CN108456250B
(zh)
*
|
2017-02-17 |
2025-11-28 |
恺兴生命科技(上海)有限公司 |
靶向il-13ra2的抗体及其应用
|
|
KR20240060739A
(ko)
|
2017-02-20 |
2024-05-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
CA3051062C
(en)
|
2017-02-28 |
2023-09-26 |
Affimed Gmbh |
Tandem diabody for cd16a-directed nk-cell engagement
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
US11939385B2
(en)
|
2017-05-16 |
2024-03-26 |
ALX Oncology Inc. |
Activatable antibodies and methods of use thereof
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
US11427826B2
(en)
|
2017-08-11 |
2022-08-30 |
City of Hopw |
RNA aptamers against transferrin receptor (TfR)
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
JP2020533380A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
US20200254093A1
(en)
|
2017-09-14 |
2020-08-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
TWI713843B
(zh)
*
|
2017-09-30 |
2020-12-21 |
大陸商科濟生物醫藥(上海)有限公司 |
標靶bcma的抗體及其應用
|
|
JP7227630B2
(ja)
|
2017-10-12 |
2023-02-22 |
マックマスター ユニバーシティー |
Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
WO2019108900A1
(en)
|
2017-11-30 |
2019-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
BR112020013086A2
(pt)
*
|
2017-12-27 |
2020-12-08 |
Teneobio, Inc. |
Anticorpos específicos de heterodímero de cd3-delta/épsilon
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
SG11202007579TA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
CN112119099A
(zh)
|
2018-03-02 |
2020-12-22 |
Cdr-生物科技股份有限公司 |
三特异性抗原结合蛋白
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
SG11202009036YA
(en)
|
2018-03-30 |
2020-10-29 |
Merus Nv |
Multivalent antibody
|
|
EP3774914A2
(en)
|
2018-04-13 |
2021-02-17 |
Affimed GmbH |
Nk cell engaging antibody fusion constructs
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
SG11202011306TA
(en)
|
2018-05-16 |
2020-12-30 |
Janssen Biotech Inc |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
AU2019277029C1
(en)
*
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
MX2021000532A
(es)
|
2018-07-19 |
2021-04-12 |
Regeneron Pharma |
Receptores antigénicos quiméricos con especificidad para bcma y usos de estos.
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
BR112020024074A2
(pt)
|
2018-07-20 |
2021-02-17 |
Teneobio, Inc. |
anticorpos de cadeia pesada com ligação a cd19
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3833385A4
(en)
|
2018-08-08 |
2021-12-22 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
PT3844267T
(pt)
|
2018-08-31 |
2025-09-30 |
Novartis Ag |
Métodos de preparação de células que expressam recetor de antigénio quimérico
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN109293772B
(zh)
*
|
2018-09-25 |
2020-09-29 |
上海邦耀生物科技有限公司 |
靶向bcma蛋白的抗体、嵌合抗原受体和药物
|
|
US20220003772A1
(en)
|
2018-10-31 |
2022-01-06 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
BR112021010615A2
(pt)
*
|
2018-12-20 |
2021-11-03 |
Cedars Sinai Medical Center |
Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
AU2020229806A1
(en)
|
2019-02-25 |
2021-07-29 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
SG11202109002XA
(en)
|
2019-03-21 |
2021-09-29 |
Regeneron Pharma |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
AU2020267057A1
(en)
|
2019-04-30 |
2021-11-18 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
|
|
JP2022531001A
(ja)
*
|
2019-05-03 |
2022-07-05 |
セルジーン コーポレーション |
抗ｂｃｍａ抗体コンジュゲート、そのコンジュゲートを含む組成物ならびにそのコンジュゲートの製造および使用方法
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
AU2020325021B2
(en)
|
2019-08-05 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
EP4010373A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
MX2022001626A
(es)
|
2019-08-06 |
2022-03-02 |
Glaxosmithkline Ip Dev Ltd |
Composiciones biofarmaceuticas y procedimientos conexos.
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
JP7773466B2
(ja)
|
2019-11-26 |
2025-11-19 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
EP4076503A4
(en)
*
|
2019-12-20 |
2024-04-03 |
MedImmune, LLC |
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN 3
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
US20230078007A1
(en)
*
|
2020-02-24 |
2023-03-16 |
The Regents Of The University Of California |
In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells
|
|
MX2022010685A
(es)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
WO2021222578A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
|
PH12022553023A1
(en)
|
2020-05-11 |
2024-03-04 |
Janssen Biotech Inc |
Methods for treating multiple myeloma
|
|
CN115666727A
(zh)
|
2020-05-19 |
2023-01-31 |
詹森生物科技公司 |
包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
|
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
PE20230464A1
(es)
|
2020-06-30 |
2023-03-14 |
Teneobio Inc |
Union de anticuerpos multiespecificos a bcma
|
|
WO2022002033A1
(zh)
*
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
具有H2L2与HCAb结构的结合蛋白
|
|
AU2021300362A1
(en)
|
2020-07-01 |
2023-02-23 |
ARS Pharmaceuticals, Inc. |
Anti-ASGR1 antibody conjugates and uses thereof
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202227124A
(zh)
|
2020-08-21 |
2022-07-16 |
瑞士商諾華公司 |
用於體內產生ｃａｒ表現細胞的組成物和方法
|
|
WO2022090556A1
(en)
|
2020-11-02 |
2022-05-05 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
WO2022184082A1
(en)
*
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
US20240158505A1
(en)
*
|
2021-03-26 |
2024-05-16 |
Theranotics Co., Ltd. |
B7-h3 antibody or antigen-binding fragment thereof, and use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｃｒに結合する多機能性分子およびその使用
|
|
TW202309294A
(zh)
|
2021-04-27 |
2023-03-01 |
瑞士商諾華公司 |
病毒載體生產系統
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022248870A1
(en)
|
2021-05-28 |
2022-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
EP4347660A4
(en)
|
2021-06-01 |
2025-06-04 |
Triumvira Immunologics USA, Inc. |
CLAUDIN-18.2 T-CELL ANTIGEN COUPLER AND USES THEREOF
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
WO2023012669A2
(en)
|
2021-08-03 |
2023-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
|
WO2023019398A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Utc Therapeutics (Shanghai) Co., Ltd. |
Bcma targetting antibodies, chimeric antigen receptors, and uses thereof
|
|
JP2024531364A
(ja)
|
2021-08-20 |
2024-08-29 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
US20240360216A1
(en)
*
|
2021-09-03 |
2024-10-31 |
Novoprotein Scientific Inc. |
Anti-cd3 humanized antibody
|
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
WO2023081705A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
EP4469484A1
(en)
|
2022-01-25 |
2024-12-04 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapy for cancer
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
TW202409280A
(zh)
|
2022-07-08 |
2024-03-01 |
新加坡科技研究局 |
Cnx抗原結合分子
|
|
CN120129696A
(zh)
|
2022-09-01 |
2025-06-10 |
乔治亚大学研究基金公司 |
用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
CN120303298A
(zh)
|
2022-12-05 |
2025-07-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
使用b细胞成熟抗原拮抗剂的治疗方法
|
|
CN121263449A
(zh)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
Cd19/cd38多特异性抗体
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025174963A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026062240A1
(en)
|
2024-09-20 |
2026-03-26 |
Albatroz Therapeutics Pte. Ltd. |
Inhibition of calnexin for the treatment of inflammatory bowel disease
|
|
WO2026072671A1
(en)
|
2024-09-24 |
2026-04-02 |
City Of Hope |
Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
|
|
WO2026094004A2
(en)
|
2024-11-04 |
2026-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for multiple myeloma with anti-bcma antigen binding protein
|